Literature DB >> 21294124

Effect of fixation on brain and lymphoreticular vCJD prions and bioassay of key positive specimens from a retrospective vCJD prevalence study.

Jonathan D F Wadsworth1, Inmaculada Dalmau-Mena, Susan Joiner, Jacqueline M Linehan, Catherine O'Malley, Caroline Powell, Sebastian Brandner, Emmanuel A Asante, James W Ironside, David A Hilton, John Collinge.   

Abstract

Anonymous screening of lymphoreticular tissues removed during routine surgery has been applied to estimate the UK population prevalence of asymptomatic vCJD prion infection. The retrospective study of Hilton et al (J Pathol 2004; 203: 733-739) found accumulation of abnormal prion protein in three formalin-fixed appendix specimens. This led to an estimated UK prevalence of vCJD infection of ∼1 in 4000, which remains the key evidence supporting current risk reduction measures to reduce iatrogenic transmission of vCJD prions in the UK. Confirmatory testing of these positives has been hampered by the inability to perform immunoblotting of formalin-fixed tissue. Animal transmission studies offer the potential for 'gold standard' confirmatory testing but are limited by both transmission barrier effects and known effects of fixation on scrapie prion titre in experimental models. Here we report the effects of fixation on brain and lymphoreticular human vCJD prions and comparative bioassay of two of the three prevalence study formalin-fixed, paraffin-embedded (FFPE) appendix specimens using transgenic mice expressing human prion protein (PrP). While transgenic mice expressing human PrP 129M readily reported vCJD prion infection after inoculation with frozen vCJD brain or appendix, and also FFPE vCJD brain, no infectivity was detected in FFPE vCJD spleen. No prion transmission was observed from either of the FFPE appendix specimens. The absence of detectable infectivity in fixed, known positive vCJD lymphoreticular tissue precludes interpreting negative transmissions from vCJD prevalence study appendix specimens. In this context, the Hilton et al study should continue to inform risk assessment pending the outcome of larger-scale studies on discarded surgical tissues and autopsy samples.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21294124     DOI: 10.1002/path.2821

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

1.  First demonstration of transmissible spongiform encephalopathy-associated prion protein (PrPTSE) in extracellular vesicles from plasma of mice infected with mouse-adapted variant Creutzfeldt-Jakob disease by in vitro amplification.

Authors:  Paula Saá; Oksana Yakovleva; Jorge de Castro; Irina Vasilyeva; Silvia H De Paoli; Jan Simak; Larisa Cervenakova
Journal:  J Biol Chem       Date:  2014-08-25       Impact factor: 5.157

2.  Accelerated, spleen-based titration of variant Creutzfeldt-Jakob disease infectivity in transgenic mice expressing human prion protein with sensitivity comparable to that of survival time bioassay.

Authors:  Sophie Halliez; Fabienne Reine; Laetitia Herzog; Emilie Jaumain; Stéphane Haïk; Human Rezaei; Jean-Luc Vilotte; Hubert Laude; Vincent Béringue
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

3.  Interventions to reduce the risk of surgically transmitted Creutzfeldt-Jakob disease: a cost-effective modelling review.

Authors:  Matt Stevenson; Lesley Uttley; Jeremy E Oakley; Christopher Carroll; Stephen E Chick; Ruth Wong
Journal:  Health Technol Assess       Date:  2020-02       Impact factor: 4.014

4.  Lack of prion infectivity in fixed heart tissue from patients with Creutzfeldt-Jakob disease or amyloid heart disease.

Authors:  Suzette A Priola; Anne E Ward; Sherman A McCall; Matthew Trifilo; Young Pyo Choi; Laura Solforosi; R Anthony Williamson; Justin T Cruite; Michael B A Oldstone
Journal:  J Virol       Date:  2013-06-19       Impact factor: 5.103

5.  Highly efficient prion transmission by blood transfusion.

Authors:  Olivier Andréoletti; Claire Litaise; Hugh Simmons; Fabien Corbière; Séverine Lugan; Pierrette Costes; François Schelcher; Didier Vilette; Jacques Grassi; Caroline Lacroux
Journal:  PLoS Pathog       Date:  2012-06-21       Impact factor: 6.823

6.  Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey.

Authors:  O Noel Gill; Yvonne Spencer; Angela Richard-Loendt; Carole Kelly; Reza Dabaghian; Lynnette Boyes; Jacqueline Linehan; Marion Simmons; Paul Webb; Peter Bellerby; Nick Andrews; David A Hilton; James W Ironside; Jon Beck; Mark Poulter; Simon Mead; Sebastian Brandner
Journal:  BMJ       Date:  2013-10-15

7.  Experimental sheep BSE prions generate the vCJD phenotype when serially passaged in transgenic mice expressing human prion protein.

Authors:  Susan Joiner; Emmanuel A Asante; Jacqueline M Linehan; Lara Brock; Sebastian Brandner; Susan J Bellworthy; Marion M Simmons; James Hope; John Collinge; Jonathan D F Wadsworth
Journal:  J Neurol Sci       Date:  2017-12-29       Impact factor: 3.181

8.  Prion infectivity in the spleen of a PRNP heterozygous individual with subclinical variant Creutzfeldt-Jakob disease.

Authors:  Matthew T Bishop; Abigail B Diack; Diane L Ritchie; James W Ironside; Robert G Will; Jean C Manson
Journal:  Brain       Date:  2013-02-28       Impact factor: 13.501

9.  Estimation of the exposure of the UK population to the bovine spongiform encephalopathy agent through dietary intake during the period 1980 to 1996.

Authors:  Chu-Chih Chen; Yin-Han Wang
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.